Drug development

#Drug development #Drug discovery #Regulatory #Whitepaper

Whitepaper: Learn how to comply with mandatory USP revision

A new whitepaper from Mettler Toledo is available for free download entitled ‘Ensure Compliance with US Pharmacopeia’. Key highlights: Comprehensive explanation of the newly revised USP General Chapters 41 and 1251 Practical advice on how to implement these revised requirements effectively Guidance to help ensure compliance with updated USP weighing… Read More

#News

Cancer cell
#Cancer #Drug development #ESMO #Liver disease #Oncology

Autotaxin inhibition: unlocking new frontiers in cancers and beyond 

Richard Staines reviews the emergence of autotaxin (ATX) inhibition as a transformative approach in oncology, with the potential to expand into other diseases, including liver malignancies.  Autotaxin (ATX) inhibition is emerging as a promising therapeutic strategy in oncology, with potential relevance to chronic liver disease and beyond. Although early trials in idiopathic pulmonary fibrosis (IPF) faced… Read More

#Exclusive Content

Synthetic DNA
#Drug development #Genomics #Precision medicine

6-Base sequencing: A tool for better drug development 

Tom Charlesworth, Director of Marketing Strategy and Corporate Development at biomodal examines how 6-base sequencing can unlock advancements in precision medicine.  Call it precision medicine, Genomics 3.0, or the age of multi-omics. However you choose to describe it, the underlying meaning is the same: Our ability to collect and analyse… Read More

#Exclusive Content

Stem cells
#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Technical Guide: Introducing the Brain-Chip R1

A new Technical Guide is now available from Emulate entitled ‘Characterization of the Brain-Chip R1: A First-in-Class, Isogenic Model of the Human Neurovascular Unit‘. Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight,… Read More

#News

#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Introducing the Brain-Chip R1: A new era for human-relevant BBB & NVU research

Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight, stable barrier throughout a four-day experimental window Features a streamlined, 12-day direct-to-chip workflow with no pre-plating or expansion steps, enabling robust and reproducible performance… Read More

#Resources #Technical Notes

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug development #NHS

eXmoor and NHS trust partner on cell & gene therapies 

Cell and gene therapy CDMO eXmoor Pharma has partnered with Royal Free London NHS Foundation Trust to collaborate on the development and manufacturing of cell and gene therapies in the UK. The collaboration brings together eXmoor’s later-phase clinical manufacturing capabilities  with the trust’s Cell and Vector Innovation Centre (CVIC), which has early-phase clinical manufacturing expertise. The organisations… Read More

#Business & Investment #News

Deal making concept
#Biomarkers #Biotechnology #Drug development

Mursla Bio partners with pharma company on drug development 

Biotechnology company Mursla Bio has announced a partnership with a pharma company to advance biomarker-guided drug development.  While the company has not been named, Mursla Bio says it is a global pharma leader recognised for its expertise in biomarker-guided precision medicine in metabolic dysfunction-associated steatohepatitis (MASH).  Under the collaboration, Mursla… Read More

#Business & Investment #News

amino acids chain
#Drug development #Drug discovery #Live cell analysis #Protein degradation #Whitepaper

Whitepaper: See what’s driving the next wave of degrader discovery

The kinetic profile of degrader compounds is critical to optimised design, showing how live-cell kinetic analysis transforms discovery. A new Whitepaper from Promega entitled ‘Beyond Endpoints: Capturing and Translating The Dynamics of Targeted Protein Degradation‘ reveals how tracking protein dynamics in live cells delivers richer, more actionable data to… Read More

#News

#Drug development #Drug discovery #Live cell analysis #Protein degradation #Whitepaper

See what’s driving the next wave of degrader discovery

The kinetic profile of degrader compounds is critical to optimised design, showing how live-cell kinetic analysis transforms discovery. This Whitepaper reveals how tracking protein dynamics in live cells delivers richer, more actionable data to improve compound optimisation across programmes. The Whitepaper will discuss: Why kinetic data deliver deeper context than… Read More

#Resources #Whitepapers

India on globe
#Drug development #Drug discovery #India #Investment

Syngene International commits new investment to drug discovery

Syngene International has announced new investment in peptide laboratory and advanced automation to accelerate drug discovery and development in India.  The investments include a dedicated peptide laboratory in Bengaluru and the integration of automation across Drug Metabolism and Pharmacokinetics (DMPK) and Direct-to-Biology (D2B) workflows in Hyderabad. The company hopes the… Read More

#Business & Investment #News

Molecules
#Drug design #Drug development #Drug discovery #Structural biology #Webinar

Tomorrow: Drive breakthroughs with structure-guided drug design

Join DDW and Curia on 14 October for a webinar on how X-ray crystallography can accelerate the drug design process. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several… Read More

#News

Female researcher in a laboratory
#CRO #Drug development #Drug discovery #Translational chemistry

Integrating translational and clinical research to advance drug development

Dr Kenneth Barr, Head of Strategic Collaborations at Syngene, explores how early-phase drug development is moving towards integrated translational strategies.   Drug development continues to grow in complexity, risk, and cost. With timelines stretching over a decade and the average spend per new drug exceeding $2.6 billion, many pharmaceutical and… Read More

#Exclusive Content

#Drug design #Drug development #Webinar

Webinar: How can a structure-based strategy fast-track drug delivery?

Join DDW and Curia on 14 October for a webinar on how X-ray crystallography can accelerate the drug design process. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several… Read More

#News

#Biotech #CDMO #Collaboration #Drug development

How speed and clarity decide biotech’s winners 

Dr Thomas Meins, General Manager of WuXi AppTec’s subsidiary Crelux in Munich, Germany discusses how agile collaboration helps innovators adapt and succeed. Every biotech project begins with a vision, an idea with the potential to turn science into impact. But a vision alone is not enough. Turning that idea into… Read More

#Exclusive Content